Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VCEL
stocks logo

VCEL

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
64.61M
+22.7%
-0.037
-63.33%
70.60M
+21.92%
0.050
+171.74%
98.31M
+30.43%
0.427
+12.28%
Estimates Revision
The market is revising Downward the revenue expectations for Vericel Corporation (VCEL) for FY2025, with the revenue forecasts being adjusted by -0.17% over the past three months. During the same period, the stock price has changed by 2.10%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.17%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-23.84%
In Past 3 Month
Stock Price
Go Up
up Image
+2.10%
In Past 3 Month
7 Analyst Rating
up Image0
Wall Street analysts forecast VCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCEL is 60.00 USD with a low forecast of 55.00 USD and a high forecast of 67.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 39.410
sliders
Low
55.00
Averages
60.00
High
67.00
up Image0
Current: 39.410
sliders
Low
55.00
Averages
60.00
High
67.00
TD Cowen
TD Cowen
Buy
downgrade
$72 -> $55
2025-05-09
Reason
TD Cowen
TD Cowen
Price Target
$72 -> $55
2025-05-09
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Vericel to $55 from $72 and keeps a Buy rating on the shares. The firm delivered Q1 revenue in line with its guidance for the quarter, despite facing some Epicel headwinds. While investors were likely looking for a Q1 beat, Vericel's ability to meet reiterated 2025 guidance should be the primary focus going forward. TD Cowen sees guidance of 20%-23% growth as achievable and expect stronger second half of 2025 contributions from Arthro and an expanding MACI sales force to be key drivers.
Truist Securities
Richard Newitter
Strong Buy
Maintains
$61 → $51
2025-04-11
Reason
Truist Securities
Richard Newitter
Price Target
$61 → $51
2025-04-11
Maintains
Strong Buy
Reason
Truist analyst Richard Newitter lowered the firm's price target on Vericel to $51 from $61 and keeps a Buy rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.
Truist Securities
Richard Newitter
Strong Buy
Reiterates
$67 → $61
2025-03-03
Reason
Truist Securities
Richard Newitter
Price Target
$67 → $61
2025-03-03
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$60
2025-02-28
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$60
2025-02-28
Reiterates
Strong Buy
Reason
Canaccord Genuity
Caitlin Cronin
Strong Buy
Maintains
$64 → $67
2025-02-03
Reason
Canaccord Genuity
Caitlin Cronin
Price Target
$64 → $67
2025-02-03
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$60
2025-01-15
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$60
2025-01-15
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Vericel Corp (VCEL.O) is 139.13, compared to its 5-year average forward P/E of -53.78. For a more detailed relative valuation and DCF analysis to assess Vericel Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-53.78
Current PE
139.13
Overvalued PE
587.69
Undervalued PE
-695.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
46.61
Current EV/EBITDA
27.55
Overvalued EV/EBITDA
64.26
Undervalued EV/EBITDA
28.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
8.92
Current PS
7.07
Overvalued PS
11.59
Undervalued PS
6.24

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

VCEL News & Events

Events Timeline

(ET)
2025-05-08
07:59:11
Vericel sees FY25 revenue growth 20%-23%
select
2025-05-08
07:58:28
Vericel reports Q1 EPS (23c), consensus (15c)
select
2025-01-14 (ET)
2025-01-14
15:41:07
Vericel down 10% at $52.67 after below-consensus Q4 pre-announcement
select
Sign Up For More Events
Sign Up For More Events

News

Preview
1.0
06-10Newsfilter
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025

  • Company Announcement: Vericel Corporation will participate in a fireside chat at the Truist Securities MedTech Conference on June 17, 2025, with a webcast available on their Investor Relations website.

  • About Vericel: The company specializes in advanced therapies for sports medicine and severe burn care, offering products like MACI and Epicel, which are used for cartilage repair and skin replacement, respectively.

Preview
4.0
05-23Benzinga
What Analysts Are Saying About Vericel Stock

  • Analyst Ratings Overview: In the past three months, four analysts have provided varied ratings on Vericel, with a total of three bullish and one somewhat bullish rating, while the average price target has decreased by 6.27% to $59.75.

  • Company Financial Performance: Vericel Corp shows strong financial metrics, including impressive revenue growth of 2.57%, a net margin of -21.38%, and a debt-to-equity ratio of 0.33, indicating effective cost management and sound financial structure compared to industry averages.

Preview
9.5
05-08Newsfilter
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

  • First Quarter Financial Performance: Vericel Corporation reported a record first quarter revenue of $52.6 million, with MACI revenue growing 15% to $46.3 million, despite a net loss of $11.2 million. The company also trained approximately 400 MACI Arthro surgeons and experienced over 30% biopsy growth year-to-date for these trained surgeons.

  • Future Outlook and Guidance: The company anticipates second quarter revenue growth in the low- to mid-20% range and has reaffirmed its full-year revenue guidance of 20% to 23%, while raising profitability expectations to a gross margin of 74% and adjusted EBITDA margin of 26%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vericel Corp (VCEL) stock price today?

The current price of VCEL is 39.41 USD — it has decreased -5.58 % in the last trading day.

arrow icon

What is Vericel Corp (VCEL)'s business?

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.

arrow icon

What is the price predicton of VCEL Stock?

Wall Street analysts forecast VCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCEL is 60.00 USD with a low forecast of 55.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vericel Corp (VCEL)'s revenue for the last quarter?

Vericel Corp revenue for the last quarter amounts to 52.60M USD, increased 2.57 % YoY.

arrow icon

What is Vericel Corp (VCEL)'s earnings per share (EPS) for the last quarter?

Vericel Corp. EPS for the last quarter amounts to -0.23 USD, increased 187.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vericel Corp (VCEL)'s fundamentals?

The market is revising Downward the revenue expectations for Vericel Corporation (VCEL) for FY2025, with the revenue forecasts being adjusted by -0.17% over the past three months. During the same period, the stock price has changed by 2.10%.
arrow icon

How many employees does Vericel Corp (VCEL). have?

Vericel Corp (VCEL) has 357 emplpoyees as of July 08 2025.

arrow icon

What is Vericel Corp (VCEL) market cap?

Today VCEL has the market capitalization of 1.98B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free